Cargando…
Buccal midazolam for pediatric convulsive seizures: efficacy, safety, and patient acceptability
Prolonged seizures and status epilepticus are a common acute neurological presentation in pediatric practice. As a result, there is a need for effective and safe medications that can be delivered to convulsing children to effect rapid seizure termination both in hospital and community settings. The...
Autor principal: | |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3546805/ https://www.ncbi.nlm.nih.gov/pubmed/23341735 http://dx.doi.org/10.2147/PPA.S39233 |
_version_ | 1782256115735592960 |
---|---|
author | Anderson, Mark |
author_facet | Anderson, Mark |
author_sort | Anderson, Mark |
collection | PubMed |
description | Prolonged seizures and status epilepticus are a common acute neurological presentation in pediatric practice. As a result, there is a need for effective and safe medications that can be delivered to convulsing children to effect rapid seizure termination both in hospital and community settings. The challenges of achieving intravenous access, particularly in young children, mandate alternative routes of administration for these drugs. Over the last ten years, midazolam delivered via the buccal mucosa has been demonstrated to be efficacious, safe, and acceptable to children and their caregivers, and a formulation has recently been licensed for use in Europe. The aim of this article is to review the clinical pharmacology with respect to these issues. |
format | Online Article Text |
id | pubmed-3546805 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-35468052013-01-22 Buccal midazolam for pediatric convulsive seizures: efficacy, safety, and patient acceptability Anderson, Mark Patient Prefer Adherence Review Prolonged seizures and status epilepticus are a common acute neurological presentation in pediatric practice. As a result, there is a need for effective and safe medications that can be delivered to convulsing children to effect rapid seizure termination both in hospital and community settings. The challenges of achieving intravenous access, particularly in young children, mandate alternative routes of administration for these drugs. Over the last ten years, midazolam delivered via the buccal mucosa has been demonstrated to be efficacious, safe, and acceptable to children and their caregivers, and a formulation has recently been licensed for use in Europe. The aim of this article is to review the clinical pharmacology with respect to these issues. Dove Medical Press 2013-01-10 /pmc/articles/PMC3546805/ /pubmed/23341735 http://dx.doi.org/10.2147/PPA.S39233 Text en © 2013 Anderson, publisher and licensee Dove Medical Press Ltd. This is an Open Access article which permits unrestricted noncommercial use, provided the original work is properly cited. |
spellingShingle | Review Anderson, Mark Buccal midazolam for pediatric convulsive seizures: efficacy, safety, and patient acceptability |
title | Buccal midazolam for pediatric convulsive seizures: efficacy, safety, and patient acceptability |
title_full | Buccal midazolam for pediatric convulsive seizures: efficacy, safety, and patient acceptability |
title_fullStr | Buccal midazolam for pediatric convulsive seizures: efficacy, safety, and patient acceptability |
title_full_unstemmed | Buccal midazolam for pediatric convulsive seizures: efficacy, safety, and patient acceptability |
title_short | Buccal midazolam for pediatric convulsive seizures: efficacy, safety, and patient acceptability |
title_sort | buccal midazolam for pediatric convulsive seizures: efficacy, safety, and patient acceptability |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3546805/ https://www.ncbi.nlm.nih.gov/pubmed/23341735 http://dx.doi.org/10.2147/PPA.S39233 |
work_keys_str_mv | AT andersonmark buccalmidazolamforpediatricconvulsiveseizuresefficacysafetyandpatientacceptability |